Metabolism of small antimicrobial β2,2-amino acid derivatives by murine liver microsomes

Terkel Hansen1,2, Morten K. Moe3,4, Trude Anderssen1, Morten B. Strøm1
1Department of Pharmacy, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway
2Leibniz-Institut für Analytische Wissenschaften -ISAS- e.V., Dortmund, Germany
3FRAM Centre (High North Research Centre for Climate and the Environment), Norwegian Institute for Air Research, Tromsø, Norway
4Department of Multidisciplinary Laboratory Medicine and Medical Biochemistry, Akershus University Hospital, Lørenskog, Norway

Tóm tắt

We have investigated the in vitro metabolism of three small antimicrobial β2,2-amino acid derivatives (M w < 500) that are highly potent against methicillin resistant Staphylococcus aureus, and are among the first compounds designed from small cationic antimicrobial peptides with potential for oral administration. The β2,2-amino acid derivatives are virtually completely resistant against degradation by proteases, and to further explore their drug potential, we have investigated the hepatic Phase I metabolism of this class of antimicrobial compounds. The β2,2-amino acid derivatives were incubated with murine liver microsomes and the metabolites analyzed semi-quantitatively by HPLC–MS and qualitatively by ultra performance liquid chromatography coupled to a tandem mass spectrometer which enabled identification of the metabolites by careful interpretation of the collision activated dissociation spectra. The study shows that sterically hindered β2,2-amino acid derivatives that otherwise are stable against proteolytic degradation underwent Phase I metabolism and were oxidized to a number of different metabolites depending on the structure of the β2,2-amino acid side-chains.

Tài liệu tham khảo

Ackley DC, Rockich KT, Baker TR (2004) Metabolic stability assessed by liver microsomes and hepatocytes. In: Yan Z, Caldwell GW (eds) Optimization in drug discovery: in vitro methods. Humana Press, NJ, pp 151–162 Boman HG (1995) Peptide antibiotics and their role in innate immunity. Annu Rev Immunol 13:61–92 Boman HG (2003) Antibacterial peptides: basic facts and emerging concepts. J Intern Med 254(3):197–215 Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J (2009) Bad bugs, no drugs: No ESKAPE! An update from the infectious diseases society of America. Clin Infect Dis 48(1):1–12 Cho TM, Rose RL, Hodgson E (2006) In vitro metabolism of naphthalene by human liver microsomal cytochrome P450 enzymes. Drug Metab Dispos 34(1):176–183 Corey GR, Stryjewski ME, Weyenberg W, Yasothan U, Kirkpatrick P (2009) Telavancin. Nat Rev Drug Discov 8(12):929–930 Gimenez D, Andreu C, del Olmo M-l, Varea T, Diaz D, Asensio G et al (2006) The introduction of fluorine atoms or trifluoromethyl groups in short cationic peptides enhances their antimicrobial activity. Bioorg Med Chem 14(20):6971–6978 Hagmann WK (2008) The many roles for fluorine in medicinal chemistry. J Med Chem 51(15):4359–4369 Hancock RE, Lehrer R (1998) Cationic peptides: a new source of antibiotics. Trends Biotechnol 16(2):82–88 Hansen T, Alst T, Havelkova M, Strøm MB (2010) Antimicrobial activity of small β-peptidomimetics based on the pharmacophore model of short cationic antimicrobial peptides. J Med Chem 53(2):595–606 Hansen T, Ausbacher D, Flaten GE, Havelkova M, Strøm MB (2011) Synthesis of cationic antimicrobial β2,2-amino acid derivatives with potential for oral administration. J Med Chem 54(3):858–868 Haug BE, Skar ML, Svendsen JS (2001) Bulky aromatic amino acids increase the antibacterial activity of 15-residue bovine lactoferricin derivatives. J Pept Sci 7(8):425–432 Haug BE, Stensen W, Stiberg T, Svendsen JS (2004) Bulky nonproteinogenic amino acids permit the design of very small and effective cationic antibacterial peptides. J Med Chem 47(17):4159–4162 IDSA (2004) Bad bugs, no drugs. Infectious Diseases Society of America Kirk KL (2006) Fluorine in medicinal chemistry: recent therapeutic applications of fluorinated small molecules. J Fluorine Chem 127(8):1013–1029 Li C, Haug T, Moe MK, Styrvold OB, Stensvag K (2010) Centrocins: isolation and characterization of novel dimeric antimicrobial peptides from the green sea urchin. Strongylocentrotus droebachiensi. Dev Comp Immunol 34(9):959–968 Livermore DM (2009) Has the era of untreatable infections arrived? J Antimicrob Chemother 64(Suppl 1):i29–i36 Mills RF, Adams SS, Cliffe EE, Dickinson W, Nicholson JS (1973) The metabolism of ibuprofen. Xenobiotica 3(9):589–598 Moe MK, Strøm MB, Jensen E, Claeys M (2004) Negative electrospray ionization low-energy tandem mass spectrometry of hydroxylated fatty acids: a mechanistic study. Rapid Commun Mass Spectrom 18(15):1731–1740 Neu HC (1992) The crisis in antibiotic resistance. Science 257(5073):1064–1073 Norrby SR, Nord CE, Finch R (2005) Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect Dis 5(2):115–119 Opar A (2007) Bad bugs need more drugs. Nat Rev Drug Discov 6(12):943–944 Park K, kitteringham NR, O′Neill PM (2001) Metabolism of fluorine-containing drugs. Annu Rev Pharmacol 41:443–470 Paterson JW, Conolly ME, Dollery CT, Hayes A, Cooper RG (1970) The pharmacodynamics and metabolism of propranolol in man. Eur J Clin Pharmacol 2(3):127–133 Peet NP (2010) Drug resistance: a growing problem. Drug Discov Today 15(15–16):583–586 Samuelsen O, Haukland HH, Jenssen H, Kramer M, Sandvik K, Ulvatne H, Vorland LH (2005) Induced resistance to the antimicrobial peptide lactoferricin B in Staphylococcus aureus. FEBS Lett 579(16):3421–3426 Strøm MB, Haug BE, Skar ML, Stensen W, Stiberg T, Svendsen JS (2003) The pharmacophore of short cationic antibacterial peptides. J Med Chem 46(9):1567–1570 Svenson J, Stensen W, Brandsdal B, Olav, Haug BE, Monrad J, Svendsen JS et al (2008) Antimicrobial peptides with stability toward tryptic degradation. Biochemistry 47(12):3777–3788 Tew GN, Clements D, Tang H, Arnt L, Scott RW (2006) Antimicrobial activity of an abiotic host defense peptide mimic. Biochim Biophys Acta-Biomemb 1758(9):1387–1392 Tew GN, Scott RW, Klein ML, DeGrado WF (2010) De novo design of antimicrobial polymers, foldamers, and small molecules: from discovery to practical applications. Acc Chem Res 43(1):30–39 Tindell GL, Walle T, Gaffney TE (1972) Rat liver microsomal metabolism of propranolol: identification of seven metabolites by gas chromatography-mass spectrometry. Life Sci 11((21, Part 2)):1029–1036 Tørfoss V, Ausbacher D, Cavalcanti-Jacobsen CD, Hansen T, Brandsdal BO, Havelkova M, Strøm MB (2012) Synthesis of anticancer heptapeptides containing a unique lipophilic beta(2,2) -amino acid building block. J Pept Sci. doi: 10.1002/psc.1434 Vasskog T, Berger U, Samuelsen PJ, Kallenborn R, Jensen E (2006) Selective serotonin reuptake inhibitors in sewage influents and effluents from Tromso Norway. J Chromatogr A 1115(1–2):187–195